Why nicotine pouches tingle
The tingle is mostly the alkali, not the nicotine — and a nicotine-free pouch still irritated every user in the German regulator's own study.
The tingle is mostly the alkali, not the nicotine. Every pouch on the market is deliberately made alkaline — measured pH 7.8 to 9.9 — because that is what pushes nicotine across your gum. The clearest evidence that nicotine is not the whole story is that a nicotine-free pouch still irritated every user in the German regulator’s own clinical study.
That is the short version, and it is more honest than the usual answer. What follows is what is actually established, what is still argued over, and why two pouches with the same number on the can can feel completely different.
The experiment that rules nicotine out as the sole cause
Germany’s Federal Institute for Risk Assessment (BfR) ran a clinical study with the Tobacco Dependence Outpatient Clinic at LMU Munich. Fifteen volunteers, five study days, one product each day: a pouch at nicotine-free, 6 mg, 20 mg or 30 mg held for twenty minutes, plus a standard cigarette on a separate day. BfR’s report of the oral findings is one sentence and it does a lot of work:
“While the tobacco cigarette rarely caused irritation to the oral mucosa, all nicotine pouch users reported oral mucosa irritation ranging from moderate (0–20 mg nicotine) to severe (30 mg).”
Note where the range starts. At zero milligrams — the nicotine-free arm — the irritation was still moderate, and all pouch users reported some, while the cigarette “rarely” caused any. So the sensation has a floor that exists without nicotine at all, with a nicotine-dependent increment stacked on top. That gradient is the single most useful finding on this subject and I have not seen it used anywhere.
Two honest limits on it: n=15, and the irritation was self-reported with no published scale. BfR gives the direction, not a magnitude.
Why every pouch is made alkaline on purpose
Nicotine is a weak base. BfR puts its relevant pKa at 8.0; a 2022 review in Frontiers in Neuroscience gives 8.02 and states the consequence plainly: “Since nicotine is a weak base with a pKa of 8.02, a higher pH results in a greater proportion of unprotonated, free-base nicotine.” Free-base nicotine crosses a biological membrane far more readily than the protonated form, which is why manufacturers raise the pH — and it is also, in the same breath, why it stings. The same review notes the “tradeoff, however, is greater irritation and perception of bitterness”.
How alkaline? RIVM, the Dutch public health institute, bought eleven pouches anonymously from Dutch webshops and measured each one. Its pH column runs from 7.8 to 9.9, with two products sitting at 9.9. For comparison, saliva sits around neutral. Here are the measured extremes alongside what else RIVM found in those same products:
| RIVM code | Measured pH | Declared nicotine | Measured nicotine | Pouch weight measured |
|---|---|---|---|---|
| NZ9 | 7.8 | 7.5 mg/g | 6.7 mg/g | 382 mg |
| NZ2 | 8.0 | 8.0 mg/g | 5.6 mg/g | 680 mg |
| NZ1 | 8.2 | 15.0 mg/g | 13.7 mg/g | 403 mg |
| NZ6 | 8.3 | 29.6 mg/g | 23.9 mg/g | 277 mg |
| NZ5 | 9.1 | 9.4 mg/g | 6.6 mg/g | 331 mg |
| NZ3 | 9.9 | 50.0 mg/g | 32.1 mg/g | 431 mg |
| NZ4 | 9.9 | 24.0 mg/g | 18.5 mg/g | 490 mg |
BfR’s own sample of 44 pouches gave a median pH of 8.8, “with only one product exhibiting an acidic pH”, and a median free-base fraction of 86%. Worth noting that BfR cites RIVM’s range as “8.8 to 9.9” — RIVM’s own table says 7.8 at the low end, and no product in it reads 8.8. I would cite RIVM’s table rather than BfR’s restatement of it.
Crucially, RIVM found that all eleven packs declared a pH adjuster on the packaging: E500 sodium carbonate, E501 potassium carbonate or E525 potassium hydroxide. That last one is a strong base, not a carbonate buffer. This is not an incidental ingredient — it is a design decision, present in every product examined.
And nobody will tell you the number
Here is the part I find genuinely striking. ZYN’s own ingredients page lists its components by function and includes, verbatim, “pH Adjusters – Adjusts the pH of the nicotine pouch“. No value. No compound name. No range.
FDA knows. In its technical review of the ZYN applications, pH is a formal bridging criterion, a stability-testing parameter and a basis for comparing pouches against snus — and I searched both that 68-page review and FDA’s 42-page review of the on! applications for any numeric pH value. There are none. FDA reviewed, relied on and withheld the pH of every nicotine pouch authorised in the United States. Our separate piece on pouch pH and why it changes the hit covers the absorption side of this; here the point is narrower: the number that best predicts how much a pouch stings is the one number nobody publishes.
The cooling agents, and the five-fold figure FDA redacted
Menthol and its synthetic cousins do something different from the alkali. They act on TRPM8, the receptor that reports cold — “also known as cold and menthol receptor 1 (CMR1), is activated by chemical agents such as menthol or by temperatures below 26°C”. A 2020 paper in Nature Communications states it directly: “Menthol in mints elicits coolness sensation by selectively activating TRPM8 channel.” Synthetic coolants, principally WS-3 and WS-23, “share menthol’s agonism at the cold-sensing TRPM8 receptor, reproducing its cooling sensation without the minty taste”.
Are they in pouches? FDA says yes, and then redacts the detail. From its ZYN review, with the compound and dose blanked as trade secret:
“As TPL, I note that the concentrations of (b)(4)in the Chill new products (i.e., (b)(4) mg/0.4 g or (b)(4) ppm) are at least 5 times higher than than those reported in the literature as eliciting a cooling sensation in humans (i.e., 100 ppm; Johnson, et al., 2018).”
(The doubled “than than” is FDA’s, not mine.) So: an authorised pouch contains a synthetic cooling agent at at least five times the concentration at which published research says a human feels cooling, and the identity and amount are withheld. FDA’s footnote widens it beyond one flavour: “Due to added ingredients such as sweeteners and cooling agents, FDA has determined that all new products have a non-tobacco characterizing flavor for the purposes of this review.”
RIVM found menthol in five of its eleven products. But its flavour screen covered a fixed list of eleven compounds — anethole, benzyl alcohol, dihydrocoumarin, ethyl acetate, ethyl butyrate, ethyl methylbutyrate, ethyl vanillin, isoamyl acetate, menthol, maltol and vanillin — and WS-3 and WS-23 are not on it. RIVM concedes the products “may contain other flavourings, which were not screened for here”. The only independent European survey of what is in these things could not have detected a synthetic coolant.
And a striking negative: I searched all four regulator documents — both BfR opinions and both RIVM reports — for TRPM8, TRPA1, TRPV1, WS-3, WS-23 and “cooling agent”. Zero hits in every one. No European regulator attributes the sensation to any receptor or named chemical. The only one that mentions cooling agents at all is FDA, and FDA blanks the compound.
Where the nicotine itself does come in — and why this part is unsettled
RIVM states, in its own voice, that “nicotine can give a burning sensation in the mouth and in the gastrointestinal tract”, and that a product with much higher nicotine content can produce a stronger feeling of mouth and throat irritation. Then it adds the caveat that matters: “on the basis of the evaluated studies this cannot be further quantified.”
At the receptor level there is a live dispute. A 2009 paper in Nature Neuroscience found that nicotine activates TRPA1, a chemosensory ion channel, and said so pointedly — the irritation “has been attributed to activation of nicotinic acetylcholine receptors (nAChRs) in chemosensory neurons. In contrast with this view, we found that the chemosensory cation channel transient receptor potential A1 (TRPA1) is crucially involved in nicotine-induced irritation”, concluding that “existing models of nicotine-induced irritation should be revised”. Thirteen years later, a review surveying the field since reaches the opposite conclusion: “Together these studies emphasize nAChRs as the primary mediator of nicotine’s irritant effects and not TRPA1”, and that “the precise role of TRPA1 in nicotine irritation is in need of more definition.”
I would not pick a side. What it means practically is that even the nicotine component of the tingle has no agreed mechanism — and if you see a confident explanation naming a single receptor, it is ahead of the evidence.
Why two 6 mg pouches tingle completely differently
Because almost nothing that governs the sensation is the milligram figure. Here is the same-strength comparison made by an independent laboratory, taking ZYN Cool Mint 6 mg and Rogue Spearmint 6 mg from a seven-product study — both labelled 6 mg, both mint:
| Measured property | ZYN, 6 mg | Rogue, 6 mg | Why it would change the feel |
|---|---|---|---|
| pH of the filler | 7.62 ± 0.01 | 7.43 ± 0.17 | Free-base fraction, and the alkali burn |
| Pouch weight | 0.38 ± 0.002 g | 0.69 ± 0.043 g | Contact area with the gum |
| Nicotine by mass | ~15.8 mg/g | ~9.0 mg/g | Concentration at the mucosa, not total dose |
| Moisture (oven volatiles) | 3.52 ± 0.08% | 14.70 ± 0.14% | How fast anything starts releasing at all |
| Soluble content | 78.26 ± 0.77% | 41.21 ± 0.35% | How much of the filler goes into solution |
| Nicotine released in 60 min | 96 ± 2% | 72 ± 5% | Whether the dose arrives in an hour or trails off |
Two products, the same number on the can, and almost every physical property different — one is nearly twice the weight of the other and four times as moist. The mg/g figures in that table are my own arithmetic from the measured weights and measured nicotine; everything else is as published. Important disclosure: that study was funded by Altria Client Services, and all eight authors were Altria employees at the time — Altria’s affiliate makes on!, which is ZYN’s only FDA-authorised competitor. The funder’s own product scored best on release. Read the comparison with that in mind.
There is also a direct experiment on whether the dose itself drives the burn, and the answer is: apparently not much. A Swedish Match clinical report published in FDA’s modified-risk docket held pH and humidity constant across four snus products and scored “burning sensation in the mouth and/or throat” as a pre-specified safety variable. Peak plasma nicotine across those arms spanned 9.0 to 17.7 ng/mL — nearly a doubling — while the burn scores sat between 0.75 and 1.75 on the scale throughout. The report’s own summary: “The mean score for burning sensation were very similar through all Snus sessions”. That is consistent with pH, held constant, being what mattered. It is a null result with a floor effect, from a sponsor’s own study on snus rather than pouches, so I would call it supporting rather than proof.
Does it fade?
Within a session, there is decent evidence that it does. Menthol applied to the tongue “elicits a self-desensitization effect, where a repeated presentation, even 60 mins later, induces far less irritation”, and menthol “also reduces the irritating effects of cinnamaldehyde, a TRPA1 agonist”. There is published work on oral menthol cross-desensitising to nicotine specifically, though I could only reach it through a citation rather than the paper.
Over months and years, the evidence does not support the easy story. The one study to look at chronic exposure gave menthol, nicotine and cinnamaldehyde chewing gums to 25 smokers and 30 non-smokers and found that “smokers did report nicotine burn more often (92%) than non-smokers (63%)” — more often, not less — at unchanged intensity, while “the cooling sensation of menthol was more widely distributed in the mouth of non-smokers as compared to smokers”. So chronic nicotine use appears to alter oral sensitivity, dulling the cooling rather than the burn. That study was supported in part by an unrestricted grant from Fertin Pharma, which manufactures nicotine pouches and gums.
And the honest gap: no study has looked at sensory adaptation in nicotine pouch users at all. Everything above is menthol, capsaicin or chewing gum.
When the tingle is not just a tingle
No regulator frames the sensation as a warning sign — neither BfR nor RIVM links the irritation it documents to any lesion, and none of the four documents treats it as a dose signal or a reason to stop. But FDA’s December 2025 review of the on! applications is more direct about oral effects than anything in Europe:
“A small case series documented oral mucosal changes and associated histopathological findings including parakeratosis, edema, and chronic inflammation in nicotine pouch users (Miluna-Meldere et al., 2024).”
FDA also cites a survey of 118 adults using pouches in which the most frequently reported adverse events were “mouth lesions (48%), upset stomach (39%), sore mouth (37%), sore throat (21%), and nausea (9%)”, adding that “severity of these self-reported AEs was not assessed”. Against that, a 24-week randomised trial found reduced gingival inflammation and bleeding in smokers who switched. FDA’s conclusion is a qualified one — “further research is needed to compare the risk of oral lesions associated with nicotine pouches to that of smokeless tobacco products” — and it flags its own evidence base: “Adverse experience data from industry-sponsored pharmacokinetic or BOE studies demonstrate that limited use of nicotine pouches in a study environment is generally well-tolerated.”
Practically: a tingle that arrives and subsides is the product working as designed. A white patch, a sore that persists, or bleeding gums is not a tingle and is worth showing to a dentist.
Frequently asked questions
Why does a stronger pouch sting more if it’s mostly the pH?
Because both things are true at once. BfR’s gradient went from moderate at 0–20 mg to severe at 30 mg, so the nicotine adds to a floor rather than creating it. And stronger products are often more alkaline: in RIVM’s table the two 9.9 pH products were also among the highest in nicotine.
Do nicotine-free pouches tingle?
Yes. That is the BfR finding at the top of this page — its nicotine-free arm still produced moderate oral irritation in all users. If a nicotine-free pouch tingles, the alkali and the coolants are doing it.
How long should the tingle last?
I cannot give you a sourced number. RIVM mentions a tingling feeling lasting up to fifteen minutes, but attributes it explicitly to user forums rather than to any study, so I would not treat that as a measurement.
Should I take the pouch out if it stings?
Stinging on its own is expected and is not a dose signal. Dizziness, nausea or a pounding heart is different — those are the complaints RIVM ties to nicotine content, and the sensible response is to remove the pouch and drop a tier.
Does moving the pouch around help?
It spreads the exposure rather than reducing it. Switching sides between pouches is more useful than fidgeting with one, and the pouch is not designed to be chewed.
Sources
- BfR, Health risk assessment of nicotine pouches, updated opinion no. 023/2022, 7 October 2022 — the LMU Munich clinical study, pH median and free-base fraction, pKa, labelling findings.
- RIVM, Nicotineproducten zonder tabak voor recreatief gebruik, briefrapport 2020-0152 — table B4.1 (dimensions, weights, pH and nicotine for 11 pouches), the ingredient survey and the flavour screen. Commissioned by the Ministry of Health, Welfare and Sport.
- FDA CTP, Technical Project Lead review of PMTAs, STNs PM0000593.PD1–PM0000612.PD1 (Swedish Match USA), signed 14–16 January 2025 — the cooling-agent passage and footnote 4.
- FDA CTP, Technical Project Lead review of nicotine pouch PMTAs, Helix Innovations LLC — oral health effects, the case series and the adverse-event survey.
- Platt SP et al., Dissolution and physical characterization of oral nicotine pouch products, Scientific Reports 16:4406, 6 January 2026 — tables 1, 2 and 8. Funded by Altria Client Services LLC; all eight authors were Altria employees at the time.
- Johnson NL, Patten T, Ma M, De Biasi M, Wesson DW, Chemosensory Contributions of E-Cigarette Additives on Nicotine Use, Frontiers in Neuroscience 16:893587, 19 July 2022. NIH-funded; no commercial relationships declared. A review, not primary data.
- Talavera K et al., Nicotine activates the chemosensory cation channel TRPA1, Nature Neuroscience 12:1293–1299, 13 September 2009. Publicly funded.
- Yin Y et al., Structural basis of cooling agent and lipid sensing by the cold-activated TRPM8 channel, Nature Communications, 29 July 2020.
- Hansen EØ, Arendt-Nielsen L, Boudreau SA, A Comparison of Oral Sensory Effects of Three TRPA1 Agonists in Young Adult Smokers and Non-smokers, Frontiers in Physiology 8:663, 7 September 2017. Supported in part by an unrestricted research grant from the Nicotine Science Center, Fertin Pharma.
- Bishara MA, de Guglielmo G, Cool but not harmless: synthetic cooling agents enhance nicotine reinforcement via the mesolimbic dopamine system, Neuropsychopharmacology 51:1746–1747, 23 July 2026 — a Research Highlight commentary, cited here only for the identity of WS-3 and WS-23 as TRPM8 agonists.
- CROel AB, SM WS 12 final study report, 17 June 2013, sponsor Swedish Match North Europe AB, published in FDA’s modified-risk docket — the constant-pH burn scores. Marked confidential to Swedish Match AB.
What I could not verify: the Miluna-Meldere case series itself (the publisher serves no readable text, so the description above is FDA’s summary of it), and the primary studies behind the cross-desensitisation and coolant-receptor claims, both of which sit behind blocked publishers and are cited here through documents I could open. Last verified 15 October 2026.
